Impact of Comorbidities and Glycemia at Admission and Dipeptidyl Peptidase 4 Inhibitors in Patients With Type 2 Diabetes With COVID-19: A Case Series From an Academic Hospital in Lombardy, Italy

Diabetes may unfavorably influence the outcome of coronavirus disease 19 (COVID-19), but the determinants of this effect are still poorly understood. In this monocentric study, we aimed at evaluating the impact of type 2 diabetes, comorbidities, plasma glucose levels, and antidiabetes medications on...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes care 2020-12, Vol.43 (12), p.3042-3049
Hauptverfasser:	Mirani, Marco, Favacchio, Giuseppe, Carrone, Flaminia, Betella, Nazarena, Biamonte, Emilia, Morenghi, Emanuela, Mazziotti, Gherardo, Lania, Andrea Gerardo
Format:	Artikel
Sprache:	eng
Schlagworte:	Betacoronavirus Blood Glucose Cardiovascular disease Comorbidity Coronary artery Coronary artery disease Coronaviridae Coronavirus Coronavirus Infections Coronaviruses COVID-19 Diabetes Diabetes mellitus Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - epidemiology Dipeptidyl-Peptidase IV Inhibitors - therapeutic use Glucose Health hazards Heart diseases Humans Hypertension Inhibitors Insulin Interleukin 6 Italy - epidemiology Kidney diseases Mortality Pandemics Patients Peptidase Peptidases Pneumonia, Viral Research design Respiratory diseases Risk analysis Risk Factors SARS-CoV-2 Severe acute respiratory syndrome Severe acute respiratory syndrome coronavirus 2 Sitagliptin Phosphate Survival Viral diseases
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!